Politiparty
Politiparty

119th Congress Health

H.R. 946: ORPHAN Cures Act

Introduced

  1. Introduced (completed)Feb 4, 2025
  2. Passed House (not reached)
  3. Passed Senate (not reached)
  4. To the President (not reached)
  5. Became law (not reached)

Summary

Introduced in House, Feb 4, 2025

This bill modifies certain provisions under the Medicare Drug Price Negotiation Program with respect to orphan drugs.

The Medicare Drug Price Negotiation Program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation. The program does not apply to orphan drugs that are approved to treat only one rare disease or condition.

The bill modifies these provisions so as to exclude any period in which a drug was an orphan drug from market approval calculations. It also excludes orphan drugs that are approved to treat more than one rare disease or condition from the program.

Written by the Congressional Research Service, Library of Congress.

Roll calls

0 votes on this bill

No roll call votes have been held on this bill.

Amendments

0 offered

No amendments were offered to this bill.

Cosponsors

18

Bipartisan support.

Who scored on this bill

6 points earned
  1. 1John Joyce R-PA SponsorDrew cross-party cosponsors, introduced2 events+6
See all scorers and every scoring event

Introductions and cosponsorships count toward weekly caps and show no points.

Other bills by John Joyce

History

  1. Feb 4, 2025Introduced in the House by John Joyce.
Show the full action history (3 actions)
  1. Feb 6, 2025Sponsor introductory remarks on measure. (CR H535-536)
  2. Feb 4, 2025Introduced in House
  3. Feb 4, 2025Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.